Get the Stockscreener App
0.786
2.21%
0.017
Adial Pharmaceuticals Inc stock is traded at $0.786, with a volume of 40,433.
It is up +2.21% in the last 24 hours and down -19.18% over the past month.
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
See More
Previous Close:
$0.769
Open:
$0.7637
24h Volume:
40,433
Relative Volume:
0.23
Market Cap:
$5.09M
Revenue:
-
Net Income/Loss:
$-6.07M
P/E Ratio:
-0.136
EPS:
-5.78
Net Cash Flow:
$-7.34M
1W Performance:
+6.04%
1M Performance:
-19.18%
6M Performance:
-19.80%
1Y Performance:
-16.38%
1-Day Range:
$0.761
$0.79
1-Week Range:
$0.7501
$0.85
52-Week Range:
$0.7151
$4.1699
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
Name
Adial Pharmaceuticals Inc
Sector
Industry
Phone
434-422-9800
Address
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Compare ADIL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADIL
Adial Pharmaceuticals Inc
|
0.786 | 5.09M | 0 | -6.07M | -7.34M | -5.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-30-18 | Initiated | Maxim Group | Buy |
| Oct-11-18 | Initiated | Dawson James | Buy |
Adial Pharmaceuticals Inc Stock (ADIL) Latest News
Adial Pharmaceuticals' Chief Medical Officer Presents AD04 at the Scientific Federation 7th World Congress on Nursing & Healthcare - ACCESS Newswire
Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Sweden and Estonia - ACCESS Newswire
Adial Pharmaceuticals Granted New U.S. Patent Expanding - GlobeNewswire
Adial Pharmaceuticals Granted New U.S. Patent On Method To Identify Genetic Markers In Alcohol or Opioid-Related Disorders - Marketscreener.com
Adial Granted New U.S. Patent Expanding Genetic-Based Approach For Addiction Treatment - Nasdaq
Adial Pharmaceuticals secures patent for genetic addiction treatment - Investing.com
This Groundbreaking Patent Could Transform How We Treat AddictionHere's Why Genetics Matter - StockTitan
Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Bulgaria - ACCESS Newswire
Adial Is Filling The Gap In Alcohol Use Disorder Treatment With Repurposed Drug - News & Insights
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Sees Significant Growth in Short Interest - Defense World
Adial Pharmaceuticals Awarded U.S. Patent For Genotype-Specific Treatment Of Opioid Disorders - Nasdaq
Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders - The Manila Times
Adial Pharmaceuticals Secures Patent for Genetically Targeted Treatment Methods in Addiction Therapy - Nasdaq
Adial Pharmaceuticals secures new patent for addiction treatment - Investing.com
Revolutionary Patent Win: Adial's DNA-Guided Solution Takes On $35B Addiction Crisis - StockTitan
EXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders - Yahoo Finance
Reddit (RDDT) Q4 Earnings: What To Expect - The Globe and Mail
Adial Pharmaceuticals Schedules Business Update Conference Call to Discuss Planned Acquisition of Purnovate and other Recent Developments - ACCESS Newswire
Adial Pharmaceuticals Submits Clinical Trial Applications in Six Additional European Countries - ACCESS Newswire
Clinical Trials News Live Feed - StockTitan
Adial completes key study for alcohol disorder drug - MSN
Adial Pharmaceuticals Receives European Medicines Agency (EMA) Agreement on the Pediatric Investigation Plan (PIP) for AD04 in Alcohol Use Disorder - ACCESS Newswire
ADILAdial Pharmaceuticals, Inc Latest Stock News & Market Updates - StockTitan
Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder - The Manila Times
Adial completes key study for alcohol disorder drug By Investing.com - Investing.com UK
Adial Pharmaceuticals Announces Positive Clinical Study - GlobeNewswire
Game-Changing Alcohol Addiction Treatment Clears Critical FDA Hurdle - StockTitan
EXCLUSIVE: Adial Pharmaceuticals Reveals Positive Pharmacokinetics Study Results Of AD04 For Alcohol Use Disorder - Benzinga
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 60.8% in January - Defense World
Adial Pharma stock hits 52-week low at $0.72 amid market challenges - Investing.com Nigeria
Adial Pharmaceuticals Announces Appointment of Alex Lugovoy as Head of Strategy - ACCESS Newswire
Why Bitcoin-Linked MicroStrategy Along With Adial Pharmaceuticals, Alpine Immune Sciences, Marin Software, And Tesla Are On Investors' Radars Today - MSN
Adial Pharmaceuticals to Commence Business Development Meetings - Defense World
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update - Defense World
Adial Pharmaceuticals Focuses on Strategic Growth Initiatives - TipRanks
Adial Pharmaceuticals Highlights AD04 for Alcohol Use Disorder - TipRanks
Alcohol Use Disorder Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, Companies by DelveInsight - Barchart
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Up 16.4% in December - Defense World
Adial Pharmaceuticals (NASDAQ:ADIL) Stock Quotes, Forecast and News Summary - Benzinga
Adial Pharmaceuticals’ New Purchase Agreement with Alumni Capital - TipRanks
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Drops By 71.7% - Defense World
Alcohol Use Disorder Market Set for Remarkable Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
Adial Pharmaceuticals revises CEO's compensation package By Investing.com - Investing.com South Africa
Adial Pharmaceuticals revises CEO's compensation package - Investing.com India
Adial Pharmaceuticals Inc Stock (ADIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):